Anaptysbio Inc share price today

(ANAB)

Anaptysbio Inc share price is $24.38 & ₹2,064.62

$24.38

▲

-0.58

(-2.32%)

Market is closed - opens 8 PM, 03 Dec 2024

View live Anaptysbio Inc share price in Dollar and Rupees. Guide to invest in Anaptysbio Inc from India. Also see the sentimental analysis on Indian investors investing in Anaptysbio Inc. Get details on the Indian mutual funds that are investing in Anaptysbio Inc. Get Analyst recommendations and forecasts along with all the Anaptysbio Inc's financials.

Anaptysbio Inc share price movements

$22.43
$24.55
$24.38
8.02%
Downside
Day's Volatility :8.66%
Upside
0.69%
$14.70
$41.31
$24.38
39.71%
Downside
52 Weeks Volatility :64.42%
Upside
40.98%

Anaptysbio Inc Returns

Period	Anaptysbio Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-32.43%	-6.2%	0.0%
6 Months	2.74%	1.7%	0.0%
1 Year	56.38%	11.6%	0.0%
3 Years	-20.4%	12.9%	-18.1%

Anaptysbio Inc Key Statistics

in dollars & INR

Market Capitalization	$764.4M
Revenue TTM	$57.2M
EBITDA	$-139.4M
Earnings Per Share (EPS)	$-6.05
Profit Margin	-289.75%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-161.82%

How to invest in Anaptysbio Inc from India?

It is very easy for Indian residents to invest directly in Anaptysbio Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Anaptysbio Inc stock in both rupees (INR) and dollars (USD). Search for Anaptysbio Inc or ANAB on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Anaptysbio Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Anaptysbio Inc shares which would translate to 0.035 fractional shares of Anaptysbio Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Anaptysbio Inc

100%

Period: Sep 3, 2024 to Dec 2, 2024. Change in 30 Days versus previous period

Search volume for Anaptysbio Inc on INDmoney from India has grown in the last 30 days as on Dec 3, 2024. 100% more investors are searching Anaptysbio Inc in the last 30 days versus the previous period.

Global Institutional Holdings in Anaptysbio Inc

EcoR1 Capital, LLC
25.62%
FMR Inc
10.88%
BlackRock Inc
5.82%
Vanguard Group Inc
5.59%
TANG CAPITAL MANAGEMENT LLC
4.37%
Boxer Capital LLC
4.27%

Analyst Recommendation on Anaptysbio Inc

Buy

75%Buy

25%Hold

0%Sell

Based on 16 Wall street analysts offering stock ratings for Anaptysbio Inc(by analysts ranked 0 to 5 stars)

Based on 16 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Anaptysbio Inc

What analysts predicted

Upside of 122.98%

Current:

$24.38

Target:

$54.36

Insights on Anaptysbio Inc

Increasing Revenue
Revenue is up for the last 3 quarters, 7.17M → 30.01M (in $), with an average increase of 49.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -46.66M → -32.85M (in $), with an average increase of 42.0% per quarter
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.6% return, outperforming this stock by 66.9%

Anaptysbio Inc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$5.0M	↓ 50.0%
Net Income	$-61.7M	↑ 105.04%
Net Profit Margin	-1.2K%	↓ 932.42%

	FY19	Y/Y Change
Revenue	$8.0M	↑ 60.0%
Net Income	$-97.3M	↑ 57.87%
Net Profit Margin	-1.2K%	↑ 16.42%

	FY20	Y/Y Change
Revenue	$75.0M	↑ 837.5%
Net Income	$-19.9M	↓ 79.53%
Net Profit Margin	-26.56%	↑ 1190.14%

	FY21	Y/Y Change
Revenue	$63.2M	↓ 15.77%
Net Income	$-57.2M	↑ 187.11%
Net Profit Margin	-90.53%	↓ 63.97%

	FY22	Y/Y Change
Revenue	$10.3M	↓ 83.72%
Net Income	$-128.7M	↑ 125.07%
Net Profit Margin	-1.3K%	↓ 1160.8%

	FY23	Y/Y Change
Revenue	$17.2M	↑ 66.78%
Net Income	$-163.6M	↑ 27.11%
Net Profit Margin	-953.66%	↑ 297.67%

	Q2 FY23	Q/Q Change
Revenue	$3.5M	↑ 151.82%
Net Income	$-39.8M	↓ 17.75%
Net Profit Margin	-1.2K%	↑ 2374.25%

	Q3 FY23	Q/Q Change
Revenue	$3.3M	↓ 4.1%
Net Income	$-37.3M	↓ 6.37%
Net Profit Margin	-1.1K%	↑ 27.18%

	Q4 FY23	Q/Q Change
Revenue	$9.0M	↑ 171.4%
Net Income	$-42.2M	↑ 13.14%
Net Profit Margin	-468.75%	↑ 655.66%

	Q1 FY24	Q/Q Change
Revenue	$7.2M	↓ 20.28%
Net Income	$-43.9M	↑ 4.09%
Net Profit Margin	-612.01%	↓ 143.26%

	Q2 FY24	Q/Q Change
Revenue	$11.0M	↑ 52.82%
Net Income	$-46.7M	↑ 6.2%
Net Profit Margin	-425.3%	↑ 186.71%

	Q3 FY24	Q/Q Change
Revenue	$30.0M	↑ 173.6%
Net Income	$-32.9M	↓ 29.59%
Net Profit Margin	-109.44%	↑ 315.86%

	FY18	Y/Y Change
Total Assets	$509.0M	↑ 54.54%
Total Liabilities	$22.6M	↑ 3.9%

	FY19	Y/Y Change
Total Assets	$435.2M	↓ 14.5%
Total Liabilities	$30.2M	↑ 33.39%

	FY20	Y/Y Change
Total Assets	$416.6M	↓ 4.28%
Total Liabilities	$19.8M	↓ 34.34%

	FY21	Y/Y Change
Total Assets	$643.1M	↑ 54.38%
Total Liabilities	$286.6M	↑ 1346.15%

	FY22	Y/Y Change
Total Assets	$610.4M	↓ 5.08%
Total Liabilities	$348.3M	↑ 21.5%

	FY23	Y/Y Change
Total Assets	$452.4M	↓ 25.88%
Total Liabilities	$364.3M	↑ 4.6%

	Q2 FY23	Q/Q Change
Total Assets	$517.1M	↓ 6.29%
Total Liabilities	$368.7M	↑ 2.2%

	Q3 FY23	Q/Q Change
Total Assets	$487.3M	↓ 5.76%
Total Liabilities	$366.9M	↓ 0.46%

	Q4 FY23	Q/Q Change
Total Assets	$452.4M	↓ 7.17%
Total Liabilities	$364.3M	↓ 0.72%

	Q1 FY24	Q/Q Change
Total Assets	$405.8M	↓ 10.29%
Total Liabilities	$358.1M	↓ 1.71%

	Q2 FY24	Q/Q Change
Total Assets	$427.4M	↑ 5.31%
Total Liabilities	$417.5M	↑ 16.6%

	Q3 FY24	Q/Q Change
Total Assets	$493.4M	↑ 15.45%
Total Liabilities	$409.1M	↓ 2.02%

	FY18	Y/Y Change
Operating Cash Flow	$-48.5M	↑ 149.54%
Investing Cash Flow	$-142.5M	↓ 41.39%
Financing Cash Flow	$223.4M	↓ 23.62%

	FY19	Y/Y Change
Operating Cash Flow	$-69.5M	↑ 43.32%
Investing Cash Flow	$131.4M	↓ 192.26%
Financing Cash Flow	$-4.5M	↓ 102.01%

	FY20	Y/Y Change
Operating Cash Flow	$-14.2M	↓ 79.64%
Investing Cash Flow	$94.5M	↓ 28.12%
Financing Cash Flow	$-879.0K	↓ 80.44%

	FY21	Y/Y Change
Operating Cash Flow	$-45.9M	↑ 224.36%
Investing Cash Flow	$38.8M	↓ 58.89%
Financing Cash Flow	$252.3M	↓ 28802.84%

	FY22	Y/Y Change
Operating Cash Flow	$-73.6M	↑ 60.26%
Investing Cash Flow	$-394.8M	↓ 1116.72%
Financing Cash Flow	$44.0M	↓ 82.55%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-25.4M	↑ 3.42%
Investing Cash Flow	$-20.5M	↓ 123.95%
Financing Cash Flow	$-13.5M	↓ 64.09%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-36.5M	↑ 43.55%
Investing Cash Flow	$30.6M	↓ 249.77%
Financing Cash Flow	$-3.1M	↓ 77.23%

Anaptysbio Inc Technicals Summary

Sell

Neutral

Buy

Anaptysbio Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Anaptysbio Inc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Anaptysbio Inc	22.27%	2.74%	56.38%	-20.4%	71.33%
Regeneron Pharmaceuticals, Inc.	-8.02%	-23.25%	-7.41%	21.97%	106.97%
Biontech Se	7.55%	17.81%	17.31%	-58.12%	421.12%
Alnylam Pharmaceuticals, Inc.	-6.28%	68.94%	46.36%	42.94%	103.66%
Vertex Pharmaceuticals Incorporated	-1.5%	-1.94%	32.83%	127.12%	108.78%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Anaptysbio Inc	NA	NA	0.0	-6.22	-1.62	-0.18	NA	2.77
Regeneron Pharmaceuticals, Inc.	18.55	18.55	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.23	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Anaptysbio Inc	Buy	$764.4M	71.33%	NA	-289.75%
Regeneron Pharmaceuticals, Inc.	Buy	$83.0B	106.97%	18.55	33.61%
Biontech Se	Buy	$28.9B	421.12%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	103.66%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$120.6B	108.78%	32.84	-4.51%

About Anaptysbio Inc

founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c

Organization	Anaptysbio Inc
Employees	117
CEO	Mr. Daniel R. Faga
Industry	Health Technology

Important FAQs about investing in Anaptysbio Inc from India :

What is Anaptysbio Inc share price today?

Anaptysbio Inc (ANAB) share price today is $24.38.

Can Indians buy Anaptysbio Inc shares?

Yes, Indians can invest in the Anaptysbio Inc (ANAB) from India.

With INDmoney, you can buy Anaptysbio Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Anaptysbio Inc at zero transaction cost.

How can I buy Anaptysbio Inc shares from India?

It is very easy to buy Anaptysbio Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Anaptysbio Inc be purchased?

Yes, you can buy fractional shares of Anaptysbio Inc with INDmoney app.

What are the documents required to start investing in Anaptysbio Inc stocks?

To start investing in Anaptysbio Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.